Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Acting Treatment in Adolescents (LATA): A Randomised Open-label 2-arm 96 Week Trial in Virologically Suppressed HIV-1-positive Adolescents Aged 12-19 Years of Age in Sub-Saharan Africa

Next Previous
Trial Profile

Long-Acting Treatment in Adolescents (LATA): A Randomised Open-label 2-arm 96 Week Trial in Virologically Suppressed HIV-1-positive Adolescents Aged 12-19 Years of Age in Sub-Saharan Africa

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Dolutegravir/lamivudine/tenofovir disoproxil fumarate; Dolutegravir/lamivudine/tenofovir-alafenamide
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms LATA

Most Recent Events

  • 29 Jul 2026 Results published in the Media Release
  • 29 Jul 2026 According to ViiV Healthcare Media Release, data from the trial were presented at the 26th International AIDS Conference (AIDS 2026). July 2026.
  • 27 Jul 2026 According to ViiV Healthcare Media Release, data from the trial to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil from 26-31 July.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top